FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283328407> ?p ?o ?g. }

• W4283328407 endingPage "867" @default.
• W4283328407 startingPage "862" @default.
• W4283328407 abstract "This study aimed to evaluate the efficacy and safety of entecavir(ETV) versus ETV maleate in Chinese patients with chronic hepatitis B(CHB). This was a randomized, double-blind, double-dummy, controlled, multicentre study. Patients were randomly assigned to receive 48 weeks of treatment with 0.5 mg/day ETV (group A) or 0.5 mg/day ETV maleate (group B), then, all patients received treatment with 0.5 mg/day ETV maleate from week 49 onwards. Patients were regularly followed up. Serum hepatitis B virus (HBV) markers were detected. Adverse events (AE) were recorded. The primary endpoint was the decline in HBV DNA in each group at the end of treatment. Secondary endpoints included the rate of HBV DNA below the lower limit of detection (LLOD) (20 I U/ml) at the end of treatment, the rate of hepatitis B e antigen (HBeAg) loss, the rate of HBeAg seroconversion and serum alanine aminotransferase (ALT) normalization. One hundred and thirty-seven (71 in group A) patients with HBeAg-positive CHB and 46 (21 in group A) patients with HBeAg-negative CHB completed the 240-week treatment and follow-up. Baseline characteristics were well balanced between the two groups. For the HBeAg-positive CHB patients, the mean HBV DNA level had similarly decreased from baseline in both groups (A: by 6.67 log10 IU/ml vs. B: by 6.74 log10 IU/ml; p > .05) at Week 240. Patients who achieved undetectable levels of serum HBV DNA (<20 IU/ml) at Week 240 were similar between groups (A:91.55% vs. B:87.88%; p > .05). Both groups achieved similar HBeAg seroconversion rates at week 240 (A:26.98% vs. B:20.97%; p > .05). Both groups achieved similar normalization of ALT (A:87.32% vs. B:83.61%; p > .05) at Week 240 (p > .05). For the HBeAg-negative CHB patients, the mean HBV DNA level had similarly decreased from baseline in both groups (A: by 6.05 log10 IU/ml vs. B: by 6.10 log10 IU/ml; p > .05) at Week 240. Patients who achieved undetectable levels of serum HBV DNA at Week 240 were similar between groups (A:100% vs. B:100%). Both groups achieved similar normalization rates (A:90.91% vs. B: 95.45%; p > .05) of ALT at Week 240 (p > .05). In conclusion, long-term ETV maleate treatment was safe and efficient in Chinese CHB predominantly of genotype B or C." @default.
• W4283328407 created "2022-06-24" @default.
• W4283328407 creator A5012394912 @default.
• W4283328407 creator A5014268039 @default.
• W4283328407 creator A5017053622 @default.
• W4283328407 creator A5018759190 @default.
• W4283328407 creator A5019031292 @default.
• W4283328407 creator A5026879317 @default.
• W4283328407 creator A5027047821 @default.
• W4283328407 creator A5027835055 @default.
• W4283328407 creator A5033736862 @default.
• W4283328407 creator A5041812006 @default.
• W4283328407 creator A5048308102 @default.
• W4283328407 creator A5051452877 @default.
• W4283328407 creator A5052880489 @default.
• W4283328407 creator A5056577685 @default.
• W4283328407 creator A5058534244 @default.
• W4283328407 creator A5072697895 @default.
• W4283328407 creator A5072816010 @default.
• W4283328407 date "2022-07-06" @default.
• W4283328407 modified "2023-09-23" @default.
• W4283328407 title "240‐week entecavir maleate treatment in Chinese chronic hepatitis B predominantly genotype B or C" @default.
• W4283328407 cites W2042565956 @default.
• W4283328407 cites W2150353364 @default.
• W4283328407 cites W2162376719 @default.
• W4283328407 cites W2415877554 @default.
• W4283328407 cites W2417014239 @default.
• W4283328407 cites W2602587173 @default.
• W4283328407 cites W2605785536 @default.
• W4283328407 cites W2768106169 @default.
• W4283328407 cites W2791839818 @default.
• W4283328407 cites W2801666689 @default.
• W4283328407 cites W4283328407 @default.
• W4283328407 cites W4323653041 @default.
• W4283328407 doi "https://doi.org/10.1111/jvh.13724" @default.
• W4283328407 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35737855" @default.
• W4283328407 hasPublicationYear "2022" @default.
• W4283328407 type Work @default.
• W4283328407 citedByCount "1" @default.
• W4283328407 countsByYear W42833284072022 @default.
• W4283328407 crossrefType "journal-article" @default.
• W4283328407 hasAuthorship W4283328407A5012394912 @default.
• W4283328407 hasAuthorship W4283328407A5014268039 @default.
• W4283328407 hasAuthorship W4283328407A5017053622 @default.
• W4283328407 hasAuthorship W4283328407A5018759190 @default.
• W4283328407 hasAuthorship W4283328407A5019031292 @default.
• W4283328407 hasAuthorship W4283328407A5026879317 @default.
• W4283328407 hasAuthorship W4283328407A5027047821 @default.
• W4283328407 hasAuthorship W4283328407A5027835055 @default.
• W4283328407 hasAuthorship W4283328407A5033736862 @default.
• W4283328407 hasAuthorship W4283328407A5041812006 @default.
• W4283328407 hasAuthorship W4283328407A5048308102 @default.
• W4283328407 hasAuthorship W4283328407A5051452877 @default.
• W4283328407 hasAuthorship W4283328407A5052880489 @default.
• W4283328407 hasAuthorship W4283328407A5056577685 @default.
• W4283328407 hasAuthorship W4283328407A5058534244 @default.
• W4283328407 hasAuthorship W4283328407A5072697895 @default.
• W4283328407 hasAuthorship W4283328407A5072816010 @default.
• W4283328407 hasBestOaLocation W42833284071 @default.
• W4283328407 hasConcept C126322002 @default.
• W4283328407 hasConcept C168563851 @default.
• W4283328407 hasConcept C197934379 @default.
• W4283328407 hasConcept C203014093 @default.
• W4283328407 hasConcept C203092338 @default.
• W4283328407 hasConcept C2522874641 @default.
• W4283328407 hasConcept C2775940106 @default.
• W4283328407 hasConcept C2776175608 @default.
• W4283328407 hasConcept C2777382497 @default.
• W4283328407 hasConcept C2777410769 @default.
• W4283328407 hasConcept C2777451964 @default.
• W4283328407 hasConcept C2777869810 @default.
• W4283328407 hasConcept C2780593183 @default.
• W4283328407 hasConcept C3020491458 @default.
• W4283328407 hasConcept C71924100 @default.
• W4283328407 hasConcept C90924648 @default.
• W4283328407 hasConceptScore W4283328407C126322002 @default.
• W4283328407 hasConceptScore W4283328407C168563851 @default.
• W4283328407 hasConceptScore W4283328407C197934379 @default.
• W4283328407 hasConceptScore W4283328407C203014093 @default.
• W4283328407 hasConceptScore W4283328407C203092338 @default.
• W4283328407 hasConceptScore W4283328407C2522874641 @default.
• W4283328407 hasConceptScore W4283328407C2775940106 @default.
• W4283328407 hasConceptScore W4283328407C2776175608 @default.
• W4283328407 hasConceptScore W4283328407C2777382497 @default.
• W4283328407 hasConceptScore W4283328407C2777410769 @default.
• W4283328407 hasConceptScore W4283328407C2777451964 @default.
• W4283328407 hasConceptScore W4283328407C2777869810 @default.
• W4283328407 hasConceptScore W4283328407C2780593183 @default.
• W4283328407 hasConceptScore W4283328407C3020491458 @default.
• W4283328407 hasConceptScore W4283328407C71924100 @default.
• W4283328407 hasConceptScore W4283328407C90924648 @default.
• W4283328407 hasIssue "10" @default.
• W4283328407 hasLocation W42833284071 @default.
• W4283328407 hasLocation W42833284072 @default.
• W4283328407 hasLocation W42833284073 @default.
• W4283328407 hasOpenAccess W4283328407 @default.
• W4283328407 hasPrimaryLocation W42833284071 @default.
• W4283328407 hasRelatedWork W1931610190 @default.

• next